Table 1.

Statistical analysis

FigureStructure of the dataType of testp value95% confidence intervals
Fig. 6C, intracellular PGRN in WT vs SORT1-KO lysates (n = 3 independent replicates)Normal distributionUnpaired t testp = 0.019630.13 to 198.5
Fig. 6D, intracellular GRN-2,3 in WT vs SORT1-KO lysates (n = 3 independent replicates)Normal distributionUnpaired t testp = 0.0486-93.93 to -0.4729
Fig. 6G, intracellular PGRN in TMEM106B-expressing HeLa lysates (n = 3 independent replicates)Normal distributionUnpaired t testp = 0.000591.99 to 157.9
Fig. 6H, intracellular GRN-2,3 in TMEM106B-expressing HeLa lysates (n = 3 independent replicates)Normal distributionUnpaired t testp = 0.0426-134.8 to -3.742
Fig. 6I, secreted PGRN in TMEM106B-expressing HeLa cell media (n = 3 independent replicates)Normal distributionUnpaired t testp = 0.4803-25.64 to 45.58
Fig. 6L, intracellular PGRN in TMEM106B-expressing PGRN KO cells pulsed with PGRN (n = 3 independent replicates)Normal distributionUnpaired t testp = 0.005536.84 to 113.6
Fig. 6M, intracellular GRN-2,3 in TMEM106B-expressing PGRN KO cells pulsed with PGRN (n = 3 independent replicates)Normal distributionUnpaired t testp = 0.0282-107.5 to -10.32
Fig. 7A, secreted PGRN in treated HAP1 cell media (n = 3 independent replicates)Normal distributionOne-way ANOVAp = 0.0009, p < 0.0001, p < 0.0001-602.5 to -207.5; -1774 to -1380; -1865 to -1471
Fig. 7C, intracellular PGRN in treated HAP1 cell lysates (n = 3 independent replicates)Normal distributionOne-way ANOVAp = 0.0007, p = 0.0332, p = 0.0151-417.2 to -153.8; -276.1 to -12.74; -301.2 to -37.84
Fig. 7D, intracellular GRN-2,3 in treated HAP1 cell lysates (n = 3 independent replicates)Normal distributionOne-way ANOVAp < 0.0001 for all 3 treatments62.35 to 104.7; 65.25 to 107.6; 56.25 to 98.55
Fig. 7I, intracellular PGRN in cathepsin L inhibitor-treated HAP1 cell lysates (n = 3 independent replicates)Normal distributionOne-way ANOVAp > 0.9999, p= 0.5501, p = 0.1055-39.01 to 37.81; -54.91 to 21.91; -70.11 to 6.712
Fig. 7J, intracellular GRN-2,3 in cathepsin L inhibitor-treated HAP1 cell lysates (n = 3 independent replicates)Normal distributionOne-way ANOVAp = 0.2116, p = 0.0144, p = 0.000362.35 to 104.7; 65.25 to 107.6; 56.25 to 98.55
Fig. 9B, intracellular PGRN in human fibroblasts (3 independent patient lines for control and FTD-GRN)Normal distributionUnpaired t testp = 0.0030-71.47 to -28.33
Fig. 9C, intracellular GRN-2,3 in human fibroblasts (3 independent patient lines for control and FTD-GRN)Normal distributionUnpaired t testp = 0.0023-75.34 to -31.98
Fig. 9D, intracellular GRN-4 in human fibroblasts (3 independent patient lines for control and FTD-GRN)Normal distributionUnpaired t testp = 0.0176-90.57 to -15.19
Fig. 9F, GRN-2,3 expression in human brain tissue (5 independent patient samples for control and FTD-GRN)Normal distributionUnpaired t testp = 0.0123-106.3 to -17.49
Fig. 9G, GRN-4 expression in human brain tissue (5 independent patient samples for control and FTD-GRN)Normal distributionUnpaired t testp = 0.0005-83.70 to -35.11
Fig. 9H, PGRN expression by ELISA in human brain tissue (5 independent patient samples for control and FTD-GRN)Normal distributionUnpaired t testp = 0.0403-78.11 to -2.261